Training activity information
Details
Interpret results from anti-viral resistance assays to include:
- CMV
- HIV
- Hep B
- Hep C
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- Why is the detection of antiviral resistance becoming increasingly important for managing certain viral infections?
- What is your understanding of common mechanisms of antiviral resistance in viruses such as CMV, HIV, Hep B, and Hep C? What knowledge do you have of the types of assays used to detect antiviral resistance (e.g., PCR, whole genome sequencing)?
- What specific skills in interpreting reports from antiviral resistance assays will you develop?
- How will you learn about the clinical implications of different antiviral resistance mutations?
- How will this activity enhance your ability to contribute to the management of patients with viral infections, especially those failing antiviral therapy?
- How will you prepare for this DTA?
- Will you review the common resistance mutations for CMV, HIV, Hep B, and Hep C?
- Will you discuss with your training officer the clinical indications for performing antiviral resistance testing?
- What challenges might arise in interpreting complex resistance reports, especially those involving multiple mutations?
- How will you understand the link between resistance mutations and treatment failure?
- How do you feel about the increasing complexity of managing viral infections due to antiviral resistance?
In action
- What specific anti-viral resistance assay results are you currently interpreting (e.g., genotypic resistance testing for HIV reverse transcriptase inhibitors, phenotypic resistance testing for cytomegalovirus antivirals)?
- How are you approaching the interpretation of these results? Why are you doing it this way (e.g., understanding the significance of specific resistance mutations, using resistance interpretation algorithms)?
- What decisions are you making regarding the potential impact of the identified resistance on antiviral therapy?
- What aspects of interpreting these results feel intuitive to you, and what requires more conscious effort (e.g., understanding the relationship between genotype and phenotype, interpreting complex resistance reports with multiple mutations)?
- How effective are your current actions in providing clinically relevant interpretations of anti-viral resistance assays?
- What challenges are you facing during the process (e.g., understanding the clinical significance of novel or less well-characterised resistance mutations)?
- What can you learn about anti-viral resistance mechanisms and the interpretation of resistance assays for different viruses as the activity unfolds?
- How does this activity connect to your understanding of virology and the management of viral infections in the context of drug resistance?
- Are there alternative approaches you could be considering if the resistance results do not correlate with the patient’s virological response (e.g., discussing with a specialist virologist, considering alternative assays)?
- What support or guidance might you need in this moment from a senior colleague or the training officer regarding the interpretation of complex anti-viral resistance reports?
- Are you working within your scope of practice when interpreting these results and considering management options?
On action
- Begin by summarising the key points of the experience working with anti-viral resistance assays.
- What were the most significant observations regarding the types of assays used (implicitly molecular, e.g., sequencing), the format of the results, or the process of interpreting complex resistance profiles for viruses like CMV, HIV, Hep B, and Hep C?
- What skills or knowledge did you develop or improve through this DTA, specifically in interpreting results from anti-viral resistance assays, understanding the significance of detected mutations or patterns, and contributing to management suggestions based on resistance findings?
- Were there any unexpected challenges (e.g., interpreting mixed viral populations, understanding the impact of specific mutations on drug susceptibility) or successes?
- What did you learn from these? In what ways did your ‘reflection-in-action’ influence your approach during the activity, such as consulting resistance databases or seeking expert advice?
- What areas for continued development have been identified, particularly concerning staying current with evolving resistance patterns or interpreting results for less common resistance mutations?
- How can you apply the learning from this activity to your routine practice when anti-viral resistance testing is performed or requested?
- Identify the specific actions or ‘next steps’ you will take to enhance your understanding of anti-viral resistance interpretation.
- What support or resources might you need to further develop in these specialised areas?
Beyond action
- Revisit your initial reflect-on-action notes for this.
- What additional insights have you gained since the initial reflection?
- Has discussing antiviral resistance cases (e.g., complex HIV resistance profiles, treatment failure in Hep B/C) at MDT meetings or with virologists/clinicians altered your perspective on clinical management?
- How did this specific antiviral resistance interpretation experience compare to interpreting antibacterial or antifungal resistance?
- What unique challenges (e.g., interpreting complex genetic data, understanding viral evolution, linking genotypes to phenotypes) have you identified across different viruses?
- Have you discussed antiviral resistance testing or management strategies during professional discussions?
- What new perspectives did this bring?
- How have the skills (e.g., interpreting complex molecular resistance reports, understanding viral drug mechanisms and resistance pathways, linking genotypic resistance to clinical implications) you developed during this DTA influenced your approach to interpreting molecular data for other pathogens?
- Have you applied the learning from this DTA, such as appreciating the complexity of managing chronic viral infections with resistance or the importance of expert advice, to other aspects of your microbiology practice?
- How does the learning from this DTA contribute to your preparedness for interpreting molecular assay results?
- What transferable skills in interpreting complex molecular data, understanding viral pathogenesis and resistance mechanisms, liaising with expert virologists/clinicians, and contributing to the long-term management of chronic viral infections, developed through this DTA, will be invaluable throughout your training and beyond?
- Identify clear actions for continued development related to antiviral resistance testing, molecular virology, or the management of chronic viral infections based on your cumulative experiences and reflections.
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 2 |
Outcome
Interpret the results of tests used to investigate common infections from a range of sample types with consideration of laboratory quality assurance and quality control |
| # 3 |
Outcome
Identify options for management of common infections based on test results and clinical context, considering infection control, guidelines and public health requirements |
| # 4 |
Outcome
Perform and interpret molecular techniques for the investigation of common infections following guidance and fulfilling health and safety requirements |